Estimation of an Optimal Chemotherapy Utilisation Rate for Upper Gastrointestinal Cancers: Setting an Evidence-Based Benchmark for the Best-Quality Cancer Care

Table 3

Comparison of optimal and actual chemotherapy utilisation rates for upper gastrointestinal cancers.

Tumour site	Optimal chemotherapy utilisation rate (%)		Actual chemotherapy utilisation rate (%)
	Any time	First course treatment	United States; NCDB [1, 8–11, 13]	United Kingdom; NYCRIS [16]	Sweden; [12]
Oesophagus	79	57	38–52	15	NR
Stomach	83	83	34	14	10–20
Pancreas	35	35	19–37	11	20–30
Primary liver	27	22	22–37	NR	NR
Gallbladder	80	33	22	NR	NR

NCDB: National Cancer Database, NYCRIS: Northern and Yorkshire Cancer Registry, and NR: not reported.